<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alexander, Lori</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Price, Matthew J.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">The Complexities of Dual Antiplatelet Therapy</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-05-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">23-25</style></pages><abstract><style  face="normal" font="default" size="100%">Dual antiplatelet therapy in patients with acute coronary syndromes is becoming more complex, making it difficult to select the optimal therapy. The optimal regimen; the potential risk for adverse events, bleeding in particular; and the role of genotyping are among the most important questions that remain unanswered.</style></abstract><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>